Key Findings
Dr. Ryan Watts, CEO of Denali Therapeutics, is scheduled to deliver an opening plenary address at the Alzheimer’s Association International Conference (AAIC) 2026, where he will highlight the company’s significant breakthroughs in delivering biologic therapies across the blood-brain barrier (BBB). Preceding this announcement, Denali received FDA accelerated approval in March 2026 for AVLAYAH™ (tividenofusp alfa-eknm) for Hunter syndrome (Mucopolysaccharidosis Type II), a biologic specifically engineered to traverse the BBB, thereby reinforcing Denali’s leadership in central nervous system (CNS) disease therapeutics.
Technical & Clinical Details
AVLAYAH™ was developed using Denali’s innovative ATV (Antibody Transport Vehicle) platform technology, which enables the effective delivery of therapeutic enzymes into the brain. Hunter syndrome is a rare genetic disorder caused by an enzyme deficiency, leading to the accumulation of glycosaminoglycans in cells throughout the body, including the brain, resulting in severe neurological symptoms. Traditional enzyme replacement therapies have shown limited efficacy in addressing cerebral symptoms due to their inability to cross the BBB. AVLAYAH™ is the first therapeutic designed to efficiently penetrate the BBB, allowing it to directly target brain pathology and offer potential neurological symptom improvement. Clinical trials have demonstrated a favorable safety profile and improvements in disease-relevant biomarkers. Additionally, Denali plans a Phase 1/1b clinical trial for DNL921, which targets amyloid beta, further expanding the application of its BBB transport technology.
Background & Context
The blood-brain barrier serves as a crucial protective mechanism for the brain but concurrently represents a major impediment for many neurological disease therapeutics attempting to reach brain targets. This formidable barrier has historically made CNS drug discovery exceptionally challenging, leading to high failure rates in developmental pipelines. Denali’s BBB transport technology overcomes this longstanding obstacle, vastly expanding the possibilities for biologic therapies not only for rare genetic conditions like Hunter syndrome but also for more prevalent neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Strategic Significance & Outlook
The FDA accelerated approval of AVLAYAH™ clinically validates Denali’s BBB transport technology, providing significant momentum to the company’s pipeline. Coupled with the upcoming clinical progression of DNL921, Denali is poised to solidify its position as a frontrunner in precision medicine for CNS disorders. This technology holds the potential to deliver more effective and accessible treatments for neurological conditions previously deemed untreatable, promising to dramatically improve patient prognoses and quality of life. Continued research into the broader applications of BBB transport technology is expected to accelerate CNS drug development across the industry.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments